Executives On The Move
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
New leaders in regulatory affairs and manufacturing at Pharnext SA and promotions at Abeona Therapeutics are among recent executive changes in the industry. Meanwhile, new directors were appointed at Onxeo SA, Avalo Therapeutics and Spero Therapeutics, among others.
New leaders in regulatory affairs and R&D at Skye Bioscience and promotions at Pieris Pharmaceuticals are among recent executive changes in the industry. Meanwhile, new directors were appointed at Summit Therapeutics, Ovid Therapeutics and Spero Therapeutics, among others.
The company created two new divisions focused on the new disease areas, bringing in former executives from Bristol Myers Squibb and Sanofi Pasteur.
Richard Pulik joins Roivant from Novartis, Hamish George joins Amplia from Dimerix, and Khiron, Immunovant, Quiapeg Pharmaceuticals and Vascular Biogenics also get new CFOs.
Hyloris picks up new chief financial officer, new chief medical officer joins Cyclo and more.
New CEOs at Mirati Therapeutics Nordic Nanovector, Rappta Therapeutics and more.
New chief financial officers at Alector, CanSino, and more.
Novartis gets new People And Organization Officer, plus new CEOs at BerGenBio, Pillar Biosciences, Pascal Biosciences, Jubilant and Civetta Therapeutics.
Aamir Malik leaves McKinsey & Co to join Pfizer as chief business innovation officer and executive vice president.
Some 22 years after founding what was one of the biggest success stories in Europe's biotech sector before a recent series of setbacks in the clinic struck, Onno van de Stolpe has decided to retire as Galapagos CEO and the search has already started for his successor.
Former Tmunity Therapeutics CFO Simona King joins Passage Bio as CFO. Rune Skeie, CFO of BerGenBio, holds the fort as interim CEO until Martin Olin joins in September.
Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Gorsky is stepping down due to a family health issue.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.